Novel psoriasis therapies and patient outcomes, part 1: Topical medications

Cutis

Volumn 95, Issue 3, 2015, Pages

  Feely, Meghan A ^a   Smith, Barry L ^a   Weinberg, Jeffrey M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTACOID; BIOLOGICAL FACTOR; CALCINEURIN INHIBITOR; COLECALCIFEROL; CORTICOSTEROID; DERMATOLOGICAL AGENT; DITHRANOL; RETINOID;

ANALOGS AND DERIVATIVES; HUMAN; PSORIASIS; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; ANTHRALIN; BIOLOGICAL FACTORS; CALCINEURIN INHIBITORS; CHOLECALCIFEROL; DERMATOLOGIC AGENTS; HUMANS; INFLAMMATION MEDIATORS; PSORIASIS; RETINOIDS;

EID: 84975824387     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Mason A, Mason J, Cork M, et al. Topical treatments for chronic plaque psoriasis: an abridged Cochrane systematic review. J Am Acad Dermatol. 2013;69:799-807.
2. Nazarian R, Weinberg JM. AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. Curr Opin Investig Drugs. 2009;10:1236-1242.
3. Moustafa F, Feldman SR. A review of phosphodiesteraseinhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology. Dermatol Online J. 2014;20:22608.
4. Halpert G, Sredni B. The effect of the novel tellurium compound AS101 on autoimmune diseases. Autoimmun Rev. 2014;13:1230-1235.
5. Ports WC, Khan S, Lan S, et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol. 2013;169:137-145.
6. Yosipovitch G, Roblin D, Traversa S, et al. A novel topical targeted anti-pruritic treatment in phase 2b development for chronic pruritus. Paper presented at: 72nd Annual Meeting of the American Academy of Dermatology; March 21-25, 2014; Denver, CO.
7. Kang S, Yi S, Griffiths CE, et al. Calcipotriene-induced improvement in psoriasis is associated with reduced interleukin-8 and increased interleukin-10 levels within lesions. Br J Dermatol. 1998;138:77-83.
8. Kristl J, Slanc P, Krasna M, et al. Calcipotriol affects keratinocyte proliferation by decreasing expression of early growth response-1 and polo-like kinase-2. Pharm Res. 2008;25:521-529.
9. Tiberio R, Bozzo C, Pertusi G, et al. Calcipotriol induces apoptosis in psoriatic keratinocytes. Clin Exp Dermatol. 2009;34:e972-e974.
10. Luger T, Seite S, Humbert P, et al. Recommendations for adjunctive basic skin care in patients with psoriasis. Eur J Dermatol. 2014;24:194-200.
11. Dermipsor reports good results in DPS-101 Phase IIb study for plaque psoriasis [press release]. Evaluate Web site. http://www.evaluategroup. com/Universal/View.aspx?type=Story&id=250042. Published October 15, 2007. Accessed February 13, 2015.
12. Rivera AM, Hsu S. Topical halobetasol propionate in the treatment of plaque psoriasis: a review. Am J Clin Dermatol. 2005;6:311-316.
13. Punwani N, Scherle P, Flores R, et al. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol. 2012;67:658-664.
14. Efficacy and safety of calcipotriol plus hydrocortisone ointment compared with tacalcitol ointment in patients with psoriasis on the face and skin folds (NCT00640822). https://clinicaltrials.gov/ct2/show/results/NCT00640822?term=NCT00640822& rank=1. Updated October 21, 2013. Accessed May 30, 2014.
15. Product candidates: targeting p-STAT3 for improved psoriasis treatment. Moleculin Web site. http://moleculin. com/product-candidates/mol4239. Accessed February 13, 2015.
16. Chowdhari S, Saini N. hsa-miR-4516 mediated downregulation of STAT3/CDK6/UBE2N plays a role in PUVA induced apoptosis in keratinocytes. J Cell Physiol. 2014;229:1630-1638.
17. Paired psoriasis lesion, comparative, study to evaluate MOL4239 in psoriasis (NCT01826201). https://clinicaltrials.gov/ct2/show/results/NCT018262 01?term=NCT01826201&rank=1§=X01256# all. Updated December 22, 2014. Accessed February 25, 2015.
18. Clinical development pipeline. Moleculin Web site. http://moleculin. com/clinical-trials/psoriasis-trials. Accessed February 13, 2015.
19. de la Brassinne M, Nikkels A. Psoriasis: state of the art 2013. Acta Clin Belg. 2013;68:433-441.
20. Ross MI. Intralesional therapy with PV-10 (Rose Bengal) for in-transit melanoma. J Surg Oncol. 2014;109:314-319.
21. Bissonnette R, Bolduc C, Maari C, et al. Efficacy and safety of topical WBI-1001 in patients with mild to moderate psoriasis: results from a randomized, double-blind placebo-controlled, phase II trial. J Eur Acad Dermatol Venereol. 2012;26:1516-1521.